Abstracts tagged "antiphospholipid syndrome"

Abstract Number: 2762 • 2017 ACR/ARHP Annual Meeting
Study of 60 Patients with Intrauterine Fetal Deaths Related to Antiphospholipid Syndrome
Mériem Belhocine¹, Laetitia Coutte², Nicolas Martin Silva³, Nathalie Morel⁴, Gaelle Guettrot-Imbert⁴, Romain Paule⁴, Michel Dreyfus⁵, Micaela Fredi⁶, Odile Souchaud-Debouverie⁷, Jean Charles Piette⁸, Veronique Le Guern⁴ and Nathalie Costedoat-Chalumeau¹, ¹Service de médecine interne Pôle médecine, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares de l’île de France, Paris, France, ²Department of Internal Medicine, Department of Internal Medicine, Cochin University Hospital, paris, France, ³Department of Internal Medicine, Department of Internal Medicine, University Hospital Center of Caen, Caen, France, ⁴Department of Internal Medicine, Department of Internal Medicine, Cochin University Hospital, Paris, France, ⁵Department of Gynecology and Obstetrics, Department of Gynecology and Obstetrics, University Hospital Center of Caen, Caen, France, ⁶Department of Rheumatology and Clinical Immunology, Rheumatology and Clinical Immunology, Rheumatology and Clinical Immunology, Spedali Civili of Brescia, Brescia, Italy, ⁷Department of Internal Medicine, Department of Internal Medicine, Poitiers University Hospital, Poitiers, France, ⁸Department of Internal Medicine, Department of Internal Medicine, University Hospital Pitié-Salpétrière, Paris, France
Background/Purpose: The antiphospholipid syndrome (APS) is defined by a combination of arterial and/or venous thrombosis, pregnancy morbidity, and persistent antiphospholipid antibodies. There is a real…
Abstract Number: 1 • 2017 ACR/ARHP Annual Meeting
Anti-Phosphatidylserine/Prothrombin Antibodies (aPS/PT) As Potential Diagnostic Markers and Risk Predictors of Venous Thrombosis and Obstetric Complications in Antiphospholipid Syndrome
Hui Shi¹, Qiongyi Hu², Hui Zheng², Jialin Teng², Gary Norman³, Jinfeng Zhou⁴ and Chengde Yang², ¹Department of Rheumatology and Immunology, Ruijin Hospital,Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China, ²Ruijin Hospital,Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China, ³INOVA Diagnostics, Inc, San Diego, China, ⁴Werfen China, Shanghai, China
Background/Purpose: , Methods: , Results: and Conclusion: Background/Purpose:The antiphospholipid syndrome (APS) is a thrombophilic disorder characterized by clinical manifestations of vascular thrombosis and obstetric complications…
Abstract Number: 2 • 2017 ACR/ARHP Annual Meeting
Identifying “Second Hit” Risk Factor(s) Associated with Thrombosis and Pregnancy Morbidity in Ethnically Diverse Antiphospholipid Antibodies Positive Patients
Yu Zuo¹, Jennifer Fan², Ravi Sarode¹, Song Zhang², Una E. Makris¹, David Karp³ and Yu-min Shen², ¹University of Texas Southwestern Medical Center, Dallas, TX, ²University of Texas Southwestern Medical Center, dallas, TX, ³Rheumatology, UT Southwestern Med Ctr, Dallas, TX
Background/Purpose: The evaluation of thrombotic and pregnancy risks associated with antiphospholipid antibodies (aPL) in individual patients without APS clinical manifestation is challenging. Our aim is…
Abstract Number: 5 • 2017 ACR/ARHP Annual Meeting
Clinical Utility of the Global Antiphospholipid Syndrome Score (GAPSS) for Risk Stratification: A Pooled Analysisfrom 2273 Patients
Savino Sciascia¹, Massimo Radin², Giovanni Sanna³, Irene Cecchi⁴, Dario Roccatello⁵ and Maria Laura Bertolaccini⁶, ¹Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy, ²Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ³Louise Coote Lupus Unit, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, London, United Kingdom, ⁴Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁵Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy, ⁶Academic Department of Vascular Surgery, Cardiovascular Division, King's College London, United Kingdom, London, United Kingdom
Background/Purpose: Recently, our group conceived a risk score for clinical manifestations of APS [the global APS score or GAPSS] that takes into account the combination…
Abstract Number: 6 • 2017 ACR/ARHP Annual Meeting
Pregnancy Outcomes in a Cohort of Women with Antiphospholipid Syndrome. 25- Years Long-Term Observation
Dana Tegzova¹, Katerina Andelova², Iva Kucerova², Vera Vlasakova³, Stejskal Jan⁴, Putova Ivana⁵, Marta Olejarova⁶ and Ctibor Dostál⁷, ¹Clinical Department, Institute of Rheumatology and Rheumatological Clinic of 1st Medical Faculty, Charles University, Prague, Czech Republic, ²Institute of Mother and Child Care, Prague, Prague, Czech Republic, ³Dept.of Internal Medicine, City Hospital Ceske Budejovice, Ceske Budejovice, Czech Republic, ⁴1st Medical Faculty, Dpt. of Pathology, Charles University, Prague, Czech Republic, ⁵Institute of Rheumatology, Dpt. of Immunology, Prague, Czech Republic, ⁶Clinical, Institute of Rheumatology and Rheumatological Clinic of 1st Medical Faculty, Charles University, Prague, Czech Republic, ⁷Institute of Rheumatology and Rheumatological Clinic of 1st Medical Faculty, Charles University, Prague, Czech Republic
Background/Purpose: The goal of this long-term project was to investigate the course of pregnancy in patients with APS (primary or secondary with SLE) in 1993-2017,…
Abstract Number: 1071 • 2016 ACR/ARHP Annual Meeting
Anti-β2GP-I-Domain 3 and Aps/PT-IgG Antibodies Identify Primary APS Patients with Both Thrombotic and Hematological Manifestations
Diego Hernández-Ramírez¹, Gabriela Hernandez-Molina², Carlos Núñez-Álvarez³, Miguel Astudillo-Angel⁴, Carlos Pacheco¹, Elizabeth Olivares-Martínez¹ and Antonio R. Cabral⁵, ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico City, Mexico, ³Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion S.Z., Mexico city, Mexico, ⁴Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ⁵Department of Medicine. Division of Rheumatology, The Ottawa Hospital.University of Ottawa, Ottawa, ON, Canada
Background/Purpose: Thrombocytopenia and hemolytic anemia (HA) are considered non-criteria clinical manifestations by the Sydney revised criteria for APS. These features can precede, follow a thrombotic…
Abstract Number: 1072 • 2016 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking Registry Analysis: Cardiovascular Risk Factors Among Different Groups of Antiphospholipid Antibody-Positive Patients
Ozan Unlu¹, Doruk Erkan², Maria Tektonidou³ and On Behalf of APS ACTION .⁴, ¹Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ²Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY, ³First Department of Internal Medicine, School of Medicine, National University of Athens, Athens, Greece, ⁴., New York, NY
Background/Purpose: Traditional cardiovascular disease (CVD) risk factors increase the risk of thrombotic clinical manifestations in antiphospholipid antibody (aPL)-positive patients. The prevalence of CVD risk factors…
Abstract Number: 1962 • 2016 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Neutrophils Are Characterized By Overexpression of P-Selectin Glycoprotein Ligand 1, a Potential Therapeutic Target
Jason S Knight¹, Patrick S. Coit¹, He Meng¹, Srilakshmi Yalavarthi¹, Paul Renauer¹, Robert C Grenn¹, Levi F Mazza¹, Hui Wang², Daniel T Eitzman² and Amr H Sawalha¹, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI
Background/Purpose: Treatment of the thrombotic manifestations of antiphospholipid syndrome (APS) primarily focuses on inhibiting clotting pathways. In an effort to identify upstream inflammatory targets that…
Abstract Number: 1965 • 2016 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking Registry Analysis: First and Recurrent Thrombosis Risk after 720 Patient-Years of Follow-up
Ozan Unlu¹, W. David Branch², Paul R. Fortin³, Maria Gerosa⁴, Guillermo J. Pons-Estel⁵, Maria Tektonidou⁶, Amaia Ugarte⁷, Doruk Erkan⁸ and On Behalf of APS ACTION .⁹, ¹Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ²Obstetrics and Gynecology, University of Utah and Intermountain Healthcare, Salt Lake City, UT, ³Medicine, CHU de Québec - Université Laval, Québec, QC, Canada, ⁴University of Milan, Istituto Ortopedico Gaetano Pini, Milano, Italy, ⁵Department of Autoimmune Diseases, Institut Clínic de Medicina i Dermatologia, Hospital Clínic de Barcelona, Barcelona, Spain, ⁶First Department of Internal Medicine, School of Medicine, National University of Athens, Athens, Greece, ⁷Hospital Universitario Cruces, Biscay, Spain, ⁸Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY, ⁹., New York, NY
Background/Purpose: APS ACTION Registry was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL)-positive patients. Previously, based on…
Abstract Number: 2086 • 2016 ACR/ARHP Annual Meeting
Hexagonal Phase Phospholipid Neutralization Assay Is the Most Sensitive but Least Specific Among Nine Tests for Detecting APS in SLE or Non-SLE Patients
Katalin Banki¹, Phillip Aleksiejuk², Jessica Patel² and Andras Perl³, ¹Clinical Pathology, SUNY Upstate Medical University, Syracuse, NY, ²Internal Medicine, SUNY Upstate Medical University, Syracuse, NY, ³Department of Medicine, Upstate Medical University, Syracuse, NY
Background/Purpose: Antiphospholipid antibody syndrome (APS) is an autoimmune, hypercoagulable state which may elicit thrombosis and pregnancy loss. Although several tests exist to guide diagnosis of…
Abstract Number: 2087 • 2016 ACR/ARHP Annual Meeting
A Type I Interferon Signature in Monocytes and Decreased Levels of Circulating Plasmacytoid Dendritic Cells in Patients with Primary Antiphospholipid Syndrome
Lucas L. van den Hoogen¹, Ruth D.E. Fritsch-Stork², Marjan A. Versnel³, Ronald H.W.M. Derksen⁴, Joel A.G. van Roon^5,6 and Timothy R.D.J. Radstake^5,6, ¹Rheumatology and Clinical Immunology, Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Immunology, Erasmus Medical Center, Rotterdam, Netherlands, ⁴Departments of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Laboratory of Translational Immunology, UMC Utrecht, Utrecht, Netherlands, ⁶Department of Rheumatology & Clinical Immunology, UMC Utrecht, Utrecht, Netherlands
Background/Purpose: In several autoimmune diseases, most notably in systemic lupus erythematosus (SLE), a type I interferon (IFN) signature has been described. This signature is thought…
Abstract Number: 2090 • 2016 ACR/ARHP Annual Meeting
Investigating the Genetic Variations of Antiphospholipid Syndrome By High-Throughput Exome Sequencing
Sung-Hoon Park¹, Chan Uk Lee¹, Ji Na Kim², Ji-Won Kim¹, Hwajeong Lee², Seong-Kyu Kim² and Jung-Yoon Choe¹, ¹Medicine, Catholic university of Daegu School of medicine, Daegu, Korea, The Republic of, ²Catholic university of Daegu School of medicine, Daegu, Korea, The Republic of
Background/Purpose: The antiphospholipid syndrome (APS) is an autoimmune disease characterized by the presence of antiphospholipid antibodies in serum together with clinical manifestations such as thrombosis,…
Abstract Number: 2092 • 2016 ACR/ARHP Annual Meeting
Plasma Soluble Triggering Receptor Expressed on Myeloid Cells-1 Is Elevated in Patients with Thrombotic Primary Antiphospholipid Syndrome.
Yair Molad^1,2, Yonatan Edel^3,4, Yael Pri-Paz Basson⁵, Elisheva Pokroy-Shapira⁶, Shirly Oren⁵, Ariela Dortort⁵ and Vitaly Kliminski^4,7, ¹Rheumatology Unit, Rheumatology Unit, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel, ²Laboratory of Inflammation Research, Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel Aviv University, Petach Tikva, Israel, ³Department of Medicine C, Beilinson Hospital, Rabib Medical Center, Petach Tikva, Israel, ⁴Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁵Rheumatology Unit, Beilinson Hospital, Rabin Medical Center, Petach Tikva, Israel, ⁶Rheumatology Unit, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel, ⁷Laboratory of Inflammation Research, Felsenstein Medical Research Center, Rabin Medical Center, Petach Tikva, Israel
Background/Purpose : Primary antiphospholipid syndrome (PAPS) is characterized by thrombotic and/or obstetrical morbidity in the presence of persistent antiphospholipid antibodies (APLA) and in the absence…
Abstract Number: 2094 • 2016 ACR/ARHP Annual Meeting
Complement Activation in Antiphospholipid Syndrome Due to the Multi-Activated Pathways of the Complement System
Hiroyuki Nakamura¹, Kenji Oku², Ryo Hisada², Kazumasa Ohmura², Masaru Kato², Toshiyuki Bohgaki², Olga Amengual², Tetsuya Horita², Shinsuke Yasuda² and Tatsuya Atsumi², ¹Medicine II, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ²Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Background/Purpose: Complement activation is proposed as one of the major thrombophilic mechanisms in antiphospholipid syndrome (APS). Among three complement pathways (classical, alternative and lectin), activation…
Abstract Number: 2095 • 2016 ACR/ARHP Annual Meeting
Autoantibodies Against High Density Lipoprotein-Associated Proteins Are Related to Elevated Oxidized Low Density Lipoprotein Levels in Antiphospholipid Syndrome
Kenji Oku¹, Uhei Shibata², Joana Batuca³, Olga Amengual⁴, Michihiro Kono², Hiroyuki Nakamura⁵, Ryo Hisada¹, Kazumasa Ohmura¹, Masaru Kato², Toshiyuki Bohgaki¹, Shinsuke Yasuda¹, Jose Delgado Alves^3,6 and Tatsuya Atsumi¹, ¹Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ²Hokkaido University Graduate School of Medicine, Sapporo, Japan, ³CEDOC/NOVA Medical School, Lisbon, Portugal, ⁴Hokkaido University,Medicine II, Sapporo, Japan, ⁵Medicine II, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ⁶Fernando Fonseca Hospital, Amadora, Portugal
Background/Purpose: Oxidized low-density lipoprotein (oxLDL), a key molecule in atherogenesis, serves as the source of anionic charged particles that bind to beta2glycoprotein I (Β2GPI) and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.